6 TECH OUTLOOKMay - 2020EditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comIn the last few decades, rapid technological advancement has significantly changed the face of the field of medical practices. The emergence of cutting-edge R&D methods has further changed the space to use a hypothesis-driven and target-based approach. However, the costly and time-consuming nature of drug research and development processes often hinders the growth of this industry, with pharmaceutical companies spending valuable resources over long periods. Another key cause of delay is the lack of efficiency in trial phases along with the increasing security concerns. Although, the standard approach to drug discovery is to identify a single molecular disease and subsequently establish a counter-acting compound has remained unchanged. The pharmaceutical industry is constantly seeking to improve and pertinent research models that will supplement the efficacy of trials. With the proliferation of digitalization across all industries, it is imperative for pharmaceutical companies to take advantage of emerging technologies that will help them gain an edge in an increasingly competitive commercial drug development environment.As the space continues to evolve, it can be challenging for pharmaceutical companies to keep up with the changes and adapt. To make this task less daunting and empower businesses to remain competitive and innovative, Pharma Tech Outlook presents to you a special edition of Drug Discovery and Development Europe 2020, featuring insights from industry leaders such as EsoCap, Vect-Horus, Glycotope and Aelian Biotechnology, offering an in-depth view of technologies that are stirring a revolution in this space. We hope this special edition will assist you in revamping your enterprise's Drug Discovery and Development strategy. Let us know your thoughts.Impact of New Technologies in Early Clinical DevelopmentCopyright © 2020 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.MAY - 08 - 2020, Vol 06 - Issue 06 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com *Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffEditor-in-ChiefStacey SmithVisualizerAsher BlakeEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul BarberSalesBrian Thomasbrian@pharmatechoutlook.comPhone: 510.556.2402sales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:Contact Us:Phone:510.556.2402, Fax:510-894-8405David ParkerTECH OUTLOOKTECH OUTLOOK
< Page 5 | Page 7 >